A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma

Table 4 Multivariate sub-group analysis of prognostic factors

Factor	MST	Univariate analysis	Multivariate analysis
Factor	MST	p-value	HR	95% CI	p-value
Age, years
< 75 (ref) vs ≥ 75	16.9 vs. 17.3 m	0.653	2.191	0.690–6.954	0.183
AFP, ng/mL
< 400 (ref) vs ≥ 400	18.1 vs. 9.9 m	0.490	1.921	0.528–6.986	0.322
Maximum diameter of liver tumors (mm)
< 50 (ref) vs ≥ 50	20.2 vs. 13.7 m	0.129	1.479	0/537–4.077	0.449
Number of liver tumors
< 10 (ref) vs ≥ 10	18.1 vs. 16.7 m	0.854	0.849	0.261–2.758	0.758
Child–Pugh score
5 (ref) vs. 6	21.5 vs. 13.2 m	0.041	3.206	1.081–9.509	0.036

Forced entry model-based Cox regression method was employed for the multivariate sub-group analysis
MST median survival time, HR Hazard ratio, CI confidence interval, AFP α-fetoprotein

ISSN: 1471-2407